Labeled 25-hydroxyvitamin D3-26,23-lactone was isolated from the serum of vitamin D-repleted rats given [3a-3H-25-hydroxyvitamin D3 24 hr prior to sacrifice. The metabolite was identified by cochromatography with the authentic lactone on straight-phase and reversed-hase high-performance liquid chromatography. Production of the lactone was abolished by nephrectomy indicating that the kidney is the site of synthesis. Homogenate of kidneys from chickens given large doses of vitamin D can carry out in vitro production of the lactone from 25-hydroxyvitamin D3. When la,25-dihydroxyvitamin D3 was used as substrate, this system produced only traces of a compound believed to be la,25-dihydroxyvitamin D3-26,23-lactone. However, incubation of rachitic chicken kidney homogenates with 25-hydroxyvitamin Dx26,23-lactone produced substantial amounts of a compound that has been identified by mass spectrometry as la,25-dihydroxyvitamin D3x2,23-lactone.
Thus, the development of a functional group on C-26 and eventual lactone formation takes place in kidney by a system acting on 25-hydroxyvitamin D3.
Since the discovery that 25-hydroxyvitamin D3 (25-OH-D3) is the major circulating form of vitamin D3 (1, 2) , the further metabolism of vitamin D has been the subject of intensive investigation. Some of the metabolites have been structurally identified and their physiological functions are well defined, but others either remain unidentified or their functions are unknown (1, 2) . The 25-hydroxylation of vitamin D3 takes place in liver; the further hydroxylation of 25-OH-D3 to la,25-dihydroxyvitamin D3 [1, Recently, a new metabolite of the vitamin has been isolated from the plasma of chickens and identified as 25-hydroxyvitamin D3-26,23-lactone (25-OH-D3-26,23-lactone) (8) . This metabolite was first observed as an interfering substance in the determination of plasma levels of 24,25-(OH)2D3 by the use of the competitive rat plasma protein radioassay method (9) . We have investigated the site of biosynthesis of 25-OH-D3-26,23-lactone from 25-OH-D3 and its la-hydroxylated analog. Our results suggest that lactone formation occurs in kidney and that the 25-OH-D3-26,23-lactone can serve as a substrate for the production by the renal la-hydroxylase system of the corresponding la-hydroxylactone [la-dihydroxyvitamin D3-26,23-lactone; 1 D3-26,23-lactone was added to each flask. After 1 hr of incubation at room temperature, the incubation mixture was extracted (15) .
In Vitro Incubation of Chicken Kidney Homogenate with Unlabeled 25-OH-D3 or 1,25.(OH)2D3. Incubation conditions were as described above except that incubation was carried out in a 4-ml reaction volume in a 125-ml erlenmeyer flask containing 400 mg of kidney tissue. In some experiments, the glucose 6-phosphate and glucose 6-phosphate dehydrogenase was replaced by 25 mM sodium succinate ( Table 1 ). The reaction was initiated by addition of either 400,ug of 25-OH-D3 or 20 Mg of 1,25-(OH)2D3 in 100 MI of 95% ethanol. The mixtures were incubated for 1 hr at 370C with shaking at 100 oscillations per min. The reaction was stopped by addition of methanol/chloroform (2:1) and extracted as described (15) .
Production of 1,25-0H)2D3-6,23-Lactone from 25-OH-D3-26,23-Lactone. Kidney homogenate (20% wt/vol) from rachitic chickens was prepared as described above in 0.19 M sucrose/15 mM Tris-acetate/1.9 mM MgCl2. Homogenate (600 mg) was incubated (total volume 4.5 ml) in 0.19 M sucrose/15 mM Tris-acetate, pH 7.4/1.9 mM MgCl2/25 mM sodium succinate in a 125-ml erlenmeyer flask using an air atmosphere and shaking at 100 oscillations per min. To initiate the reaction, 50 ,ul of ethanol containing 10ug of 25-OH-D3-26,23-lactone was added. The incubation was continued for 2.5 hr and terminated by the addition of methanol/chloroform (2:1). Extraction was carried out as described (15) . Purification of Extract by Sephadex LH-20 Chromatography. To purify the 25-OH-D3-26,23-lactone, the lipid extract of either serum or incubation medium was applied to a Sephadex LH-20 column (0.7 X 14 cm) packed in 65% CHC13/ hexane as described (16) . The column was eluted with the same Kidney homogenate was incubated with 25-OH-D3 as described. After purification of the putative lactone by high-performance liquid chromatography (see Fig. 2 ), the amount of 25-OH-D3-26,23-lactone produced in vitro was determined. solvent; the first 11 ml of eluant was discarded, and the next 25 ml was collected. HPLC of Rat Serum Extract. The purified extract of serum from either nephrectomized or sham-operated rats was dried under nitrogen, dissolved in 8% 2-PrOH/hexane and subjected to HPLC using a Zorbax-Sil column (4.6 mm X 25 cm). The HPLC was performed at a pressure of 1000 lbf/in2 (1 lbf/in2 = 6895 Pa) and a flow rate of 2 ml/min; the solvent was 8% 2-PrOH/hexane. Fractions of 0.8 ml were collected, and aliquots were counted in toluene counting solution (17) . UV absorbance was monitored at 254 nm by a model 440 absorbance detector (data not shown). The fractions containing 25-OH-D3-26,23-lactone (16-18 ml) were combined and applied to the reversed-phase HPLC using a Lichrosorb RP-18 column (4.6 mm X 25 cm) (E. Merk, Darmstadt, West Germany); this was eluted with 22% H20/MeOH at a pressure of 1300 lbf/in2 and a flow rate of 2 ml/min (Fig. 1) .
HPLC of Extracts from Incubations. To further purify the 25-OH-D3-26,23-lactone, the extracts were treated as described above, except that the straight-phase HPLC was eluted with 6% 2-PrOH/hexane ( Fig. 2A) . Fractions of 0.8 ml were collected, and an aliquot of each fraction was counted as above. The fractions containing 25-OH-D3-26,23-lactone ( Fig. 2A) were combined and applied to the reversed-phase HPLC as described above except that the elution solvent was 25% H20/MeOH. Fractions of 0.8 ml each were collected and counted (Fig. 2B) .
The extracts of tissue incubated with unlabeled 25-OH-D3 were subjected to straight-phase HPLC as described above, and the 25-(OH)2D3-26,23-lactone fraction (16-19 ml) was collected. The putative 25-OH-D3-26,23-lactone was then subjected to reversed-phase HPLC as described above, and the lactone fraction (22-27 ml) was collected.
For The fractions (16-19 ml) from straight-phase HPLC (A) were dried, dissolved in 25% H20/MeOH and subjected to HPLC on a Lichrosorb RP-18 column. HPLC was performed with 25% H20/MeOH at 1300 lbf/in2 and a flow rate of 2 ml/min. tone, the extracts were subjected to straight-phase HPLC using 15% 2-PrOH/hexane after prepurification on Sephadex LH-20. The putative 1,25-(OH)2D3-26,23-lactone from the two substrates used was collected and rechromatographed on a reversed-phase system (Zorbax-ODS) using 35% H20/MeOH as eluting solvent (Fig. 3) . The product eluting at 17 ml was collected and applied to a straight-phase silica gel column (Zorbax-Sil); this was eluted with 15% 2-PrOH/hexane. The resulting product (eluting at 29 ml) was then subjected to physical characterization.
Rat 25-OH-D3-26,23-lactone was further purified by using reversed-phase HPLC (see Fig. 1 ). The radioactive substance from the serum of sham-operated rats comigrated with authentic 25-OH-D3-26,23-lactone on this system. Furthermore, the metabolite was totally absent in nephrectomized rats (Fig.   1 ).
Kidney homogenate from vitamin D-treated chickens produced 25-OH-D3-26,23-lactone from [3a-3H]-25-OH-D3 (see Fig. 2 ). The lactone fraction from straight-phase HPLC was then subjected to reversed-phase HPLC; the radioactive peak comigrated with authentic 25-OH-D3-26,23-lactone. Liver homogenate does not produce lactone from [3a-3H]-25-OH-D3 (data not shown). Further, no lactone is produced by kidney homogenate incubated with 23,24-3H-or 26,27-3H-labeled 25-OH-D3, presumably because of isotope effect (data not shown).
The amount of 25-OH-D3-26,23-lactone produced by incubation of kidney homogenates with unlabeled 25-OH-D3 was not detectable by UV absorbance but was detectable by rat serum protein competitive binding assay.
When 25-OH-D3-26,23-lactone was incubated with kidney homogenates prepared from rachitic chickens, a product was formed that eluted just prior to 1,24R,25-(OH)3D3 on HPLC (see Fig. 3 ). By a combination of HPLC steps, sufficient material was isolated for physical characterization. Given the formation of this metabolite from 25-OH-D3-26,23-lactone, these data prove the compound to be 1,25-(OH)2D3-26,23-lactone.
In view of this result, it was of interest to determine whether chicken kidney preparations capable of converting 25-OH-D3 to its lactone could also use la,25-(OH)2D3 as substrate for conversion to the la-hydroxylactone analog. Incubation of 1a,25-(OH)2D3 with kidney homogenates from chickens given large doses of vitamin D3 gave (as expected) a product that was chromatographically identical (on two HPLC systems) with 1,24,25-(OH)3D3, but only a trace of material corresponding in elution position to la,25-(OH)2D3-26,23-lactone.
DISCUSSION
The isolation and characterization of 25-OH-D3-26,23-lactone (8) and the fact that this compound is a major vitamin D metabolite under conditions of high intake raise questions concerning its possible in vivo function, mode of biosynthesis, and site of production.
The involvement of kidney in lactone formation is evident from initial in vivo experiments with rats on a normal vitamin D diet. The results show that nephrectomy prevents the conversion of 25-OH-D3 to the lactone, whereas sham animals carry out the conversion. As anticipated, the production of 1,25-(OH)2D3 and of 24,25-(OH)2D3 was either eliminated or greatly reduced by nephrectomy (19, 20) . These results, therefore, suggest that the kidney plays an important role in production of the lactone. Kidney homogenates from chickens given high doses of vitamin D readily produced a compound that comigrated on straight-phase HPLC with authentic 25-OH-D3-26,23-lactone. The putative lactone also comigrated with authentic lactone on reversed-phase HPLC, a system known to be a very effective method for the resolution of the lactone and 24,25-(OH)2D3 compounds (8) . It is, therefore, evident from both in vivo and in vitro experiments that production of the 25-OH-D3-26,23-lactone takes place largely in the kidney (although biogenesis in other tissues cannot be excluded at this time).
Because the kidney can produce the lactone from 25-OH-D3, it was of interest to determine whether that organ could also produce a lactone from 1,25-(OH)2D3. The results show that kidney preparations from chickens given large doses of vitamin D readily convert 1,25-(OH)2D3 to 1,24,25-(OH)3D3 but produce only trace amounts of 1,25-(OH)2D3-26,23-lactone. Evidently 1,25-(OH)2D3 is a poor substrate analog for the system effecting the conversion of 25-OH-D3 to the lactone. 1,25-(OH)2D3-26,23-Lactone could be produced, however, by C-1-hydroxylation of 25-OH-D3-26,23-lactone. Incubation of 25-OH-D3-26,23-lactone with homogenates obtained from rachitic chickens known to be rich in 1-hydroxylase activity and deficient in other vitamin D hydroxylases (1, 2) converted the lactone to a more polar compound that eluted on HPLC somewhat before 1,24R,25-(OH)3D3 (Fig. 3A) . This 
